Regulation

It happened. BPC-157 and TB-500 just got a legal pharmacy lane.

HHS published its long-awaited peptide policy on October 30. Six peptides, including both halves of the Wolverine stack, can now be made by licensed pharmacies with a prescription. Here is what changed and what did not.

It happened. BPC-157 and TB-500 just got a legal pharmacy lane.

The big news

On October 30, 2026, the Department of Health and Human Services published its peptide policy in the Federal Register. This is the plan we have been tracking since it went to the White House in mid October.

The short version: HHS says it will not go after state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides, as long as they follow a list of quality rules.

The six peptides

BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon.

That is both halves of the Wolverine stack, plus KPV from the KLOW blend. For years these have mostly been sold online as "research use only." Now there is a prescription route through a real pharmacy.

Why HHS did it

In its own words, HHS wants to steer people away from research-use-only peptides from foreign manufacturers, which it says pose a safety risk, and give patients "a more controlled alternative."

HHS also said the evidence has moved since FDA staff first reviewed these peptides. For BPC-157 and TB-500, it pointed to documented human use and new lot-level test certificates from FDA-registered facilities.

How the pharmacy lane works

You still need a prescription written for you. The pharmacy has to buy the raw peptide from an FDA-registered manufacturer, with a certificate of analysis showing identity, purity, and tests for things like endotoxins, heavy metals and microbes.

Each product can contain only one peptide. So a pharmacy cannot make a premixed Wolverine blend under this policy. BPC-157 and TB-500 would come as separate products.

The policy also sets which forms are covered. BPC-157 can be injected, taken by mouth or used on the skin. TB-500 is injection only. KPV is oral or topical, and Semax is a nasal spray.

Labels must say "This is a compounded drug product. Not for resale." Pharmacies also have to report serious side effects to FDA.

What is next

Public comments are open on regulations.gov, docket HHS-OASH-2026-0496, for two weeks after publication. Law firm Foley & Lardner puts the deadline at November 13, 2026.

FDA says future rulemaking may add some or all of these peptides to the official pharmacy ingredient list. That would make it more permanent.

The fine print

This is not FDA approval. Compounded drugs are not reviewed by FDA for safety or effectiveness, and the policy says so plainly.

It is also temporary and non-binding. HHS says it can pull back on any peptide if a safety signal or quality problem shows up. FDA's own scientists had recommended against listing BPC-157 and TB-500, and a drug safety group has petitioned to block this.

GHK-Cu, the copper peptide in GLOW and KLOW, is not on the list. Neither are retatrutide or CJC-1295 and ipamorelin.

This is education, not medical advice. If you are curious, talk to a licensed clinician who can order labs and keep an eye on how you respond.

Free download

Get the free Peptide Playbook, plus new breakthroughs as they happen.

What peptides are, why people are using them, and what results people are talking about, in plain English. Sign up and we email you the Playbook right away.

Free. Unsubscribe anytime.

  • The Peptide Playbook, free in your inbox
  • Occasional updates on new developments
  • No spam, unsubscribe anytime